logo-loader
viewAcuity Bio

AcuityBio developing 'breakthrough' implant treatment for lung cancer

AcuityBio Corp CEO Dr. John Schwartz tells Proactive Investors the biotech is developing an implant called ABC-103 that prevents post-surgical lung cancer occurrence.

Dr. Schwartz says ABC-103 is in the last stages of product development, and the company is pursuing Phase 1 clinical trials.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cellmid Limited to supply rapid diagnostic tests to help in new pandemic

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...

1 day, 3 hours ago

2 min read